433 results about "Systemic lupus" patented technology

Methods and kits are provided for diagnosing of neuropsychiatric syndromes concurrent with SLE (NPSLE) and for determining whether an SLE subject is at risk of developing a neuropsychiatric disease.

The invention discloses a systemic lupus erythematosus assessment method and device based on multi-modal medical map and medical knowledge fusion, terminal equipment and a medium, and relates to the technical field of medical artificial intelligence. The method comprises the following steps: acquiring multi-dimensional medical indexes of a patient, and constructing a multi-modal medical knowledge graph of the patient associated with the indexes; pre-training the self-supervised graph neural network to obtain a patient and medical index embedding vector; grouping and constructing a feature subset combination according to medical knowledge, and training and selecting an optimal sub-model; dynamically weighting and fusing the prediction probabilities of the sub-models to obtain a comprehensive prediction probability; and screening the key indexes based on the embedded vector and quantifying the activity evaluation contribution degree of the key indexes to obtain an activity comprehensive score. The systemic lupus erythematosus evaluation method improves the accuracy and robustness of preliminary evaluation of systemic lupus erythematosus, solves the problems of data missing and sample imbalance, and is explainable in output evaluation, adaptive to primary medical treatment and capable of supporting hierarchical diagnosis and treatment.

The invention discloses a systemic lupus erythematosus interaction management method based on patient sign data modeling, and particularly relates to the field of lupus erythematosus interaction management, which comprises the following steps: collecting basic data and sign data of a patient, generating a standardized basic data set and an integrity sign data set, feature combination, feature correlation detection and factor extraction are executed, a potential feature space representing patient features is constructed, and static health behavior feature modeling is achieved; the method comprises the following steps: acquiring nurse-patient interaction behavior data, generating a preliminary interaction data set, executing interaction feature extraction and activeness judgment, and generating a standardized interaction feature matrix; a multi-dimensional feature vector and dynamic health behavior link is constructed based on patient sign data and interactive behavior features, and time sequence prediction and response feedback closed-loop optimization are combined, so that dynamic management and individualized intervention of active health behaviors of systemic lupus erythematosus patients are realized.

Various embodiments of the invention provide binding molecules for B-lymphocyte antigen (e.g., CD 19 and CD20), including antigen recognizing receptors (e.g., CARs) that target B-lymphocyte antigens (e.g., CD 19 and CD20). Embodiments of the invention also provide cells expressing such binding molecules, therapeutics compositions comprising such cells, and methods for treating diseases or disorders associated with B-lymphocyte antigen (e.g., CD19 and CD20), including a hematologic cancer, an autoimmune disease (e.g., multiple sclerosis and systemic lupus erythematosus).

Disclosed herein are methods, antibodies, and compositions for disrupting an interaction between Galectin-3 (Gal3) and viral proteins, such as proteins of the SARS-CoV-2 virus or other coronaviruses, or viral-associated host proteins. Further disclosed herein are methods, medicaments, and compositions for the treatment of a disease or a disorder in a subject, such as the treatment of a viral infection, or treatment of a fibrosis, such as lung fibrosis, that develop as a sequela of a viral infection, or cytokine release syndrome. Further disclosed herein are methods, medicaments, and compositions for the treatment of an inflammatory disease or disorder, such as inflammation of the lungs or systemic lupus erythematosus, which may be associated with neutrophil activity, in a subject. Also disclosed herein are pharmaceutical antibody formulations for the treatment of a disease, such as a coronavirus infection.

To provide a compound which is a novel proline derivative, and to provide a pharmaceutical composition comprising the compound for the treatment of diseases, for example, systemic lupus erythematosus.SOLUTION: A pharmaceutical composition comprises, as a cGAS inhibitor, a compound which is a novel proline derivative of formula (I) (where R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and G are as defined in claim 1), or a prodrug, a pharmaceutically acceptable salt, or a stereoisomer of the compound.SELECTED DRAWING: None

The invention relates to the technical field of medical data processing, and discloses a construction method and application of a systemic lupus erythematosus activity evaluation model. Expression level data of CD177 on the surface of neutrophil, anti-dsDNA antibody titer data, anti-dsDNA antibody concentration data, complement C3 concentration data and complement C4 concentration data are combined, a machine learning algorithm is utilized, and the systemic lupus erythematosus activity evaluation model is constructed. A high-precision systemic lupus erythematosus activity evaluation model is obtained through training, systemic lupus erythematosus activity can be evaluated efficiently, comprehensively and accurately, and an SLE patient is effectively assisted in seeing a doctor in time and making a correct treatment decision.

The invention discloses a neutralizing nucleic acid aptamer for targeted inhibition of a B cell activating factor and application of the neutralizing nucleic acid aptamer in treatment of systemic lupus erythematosus. The neutralizing aptamer disclosed by the invention can be used for efficiently inhibiting the combination of BAFF and specific receptors on a B cell membrane, including a BAFF receptor (BAFF-R), a human calcium regulatory cyclophilin ligand interaction molecule (TACI) and a B cell maturation antigen (BCMA), so that the proportion of plasma cells, plasma mother cells and hair growth center B cells is reduced, and finally, the generation and secretion of autoantibodies are reduced; the compound has a targeted therapeutic effect on systemic lupus erythematosus. Compared with an existing biological agent for neutralizing BAFF, the neutralizing nucleic acid aptamer has the advantages of being high in specificity, high in affinity, easy to synthesize, low in immunogenicity, low in cost, capable of being designed and programmed and the like, is a potential novel nucleic acid preparation for SLE targeted therapy, and has a good clinical transformation application prospect.

The invention provides a diagnostic marker for systemic lupus erythematosus and application of the diagnostic marker, and belongs to the technical field of biological medicine. The diagnostic marker is at least one protein of PDGFA (Platelet Derivative Growth Factor Amplification), APOD (Adenosine Polymerase Chain Reaction), CFHR5, AMDHD1 and SCGB3A1; the amino acid sequence of the PDGFA is as shown in SED ID NO. 1; the amino acid sequence of the APOD is as shown in SED ID NO. 2; the amino acid sequence of the CFHR5 is as shown in SED ID NO.3; the amino acid sequence of AMDHD1 is as shown in SED ID NO. 4; and the amino acid sequence of the SCGB3A1 is as shown in SED ID (Sequence of Identification) NO.5. According to the present invention, the five proteins are adopted as the SLE disease diagnosis biomarker independently or in the combination manner, such that advantages of high accuracy, high sensitivity and high specificity are provided, and the new target spot is provided for the diagnosis, the intervention improvement and the like of the SLE patient.

The invention discloses an E-CAR-NK cell for treating systemic lupus erythematosus and application of the E-CAR-NK cell, and belongs to the technical field of genetic engineering.A CD19 and BCMA double-target E-CAR is adopted for modifying an NK cell, and the E-CAR-NK cell is obtained; the CD19 and BCMA double-target E-CAR is composed of the following modules: a CD8 signal peptide, a CD19 scFv, a Linker, a BCMA scFv, a CD8 Hinge region, an NKG2D transmembrane region, a CD3 epsilon signal transduction region, a DAP12 costimulatory region, a 2B4 costimulatory region, and a CD3 zeta signal transduction region. Compared with a common CAR-NK cell, the E-CAR-NK cell disclosed by the invention has higher antigen sensitivity and better continuous killing ability, so that the treatment effect of SLE is improved, and the E-CAR-NK cell has lower side effects and higher safety.

The invention discloses application of docosapentaenoic acid or medicinal salt thereof in preparation of a medicine for preventing and / or treating systemic lupus erythematosus. The invention aims to provide novel application of docosapentaenoic acid in treatment of systemic lupus erythematosus. In view of various immune abnormalities existing in the systemic lupus erythematosus morbidity process, the docosapentaenoic acid has potential application value in the field of systemic lupus erythematosus treatment due to the effects of regulating immune cell functions and improving immune microenvironment.

The invention provides a biomarker for diagnosing systemic lupus erythematosus and application of the biomarker. According to the application disclosed by the invention, the expression of Ferritin in neutrophil of a systemic lupus erythematosus patient is found to be obviously reduced and is improved after treatment, the neutrophil has disease specificity and cell specificity, and the Ferritin in the neutrophil has important significance on clinical diagnosis or auxiliary diagnosis of systemic lupus erythematosus and disease condition evaluation.

The invention discloses a systemic lupus erythematosus molecular diagnosis marker based on neutrophil characteristics. The invention provides application of a substance for detecting the expression quantity of an IFIH1 gene and / or a CFLAR gene in preparation of a product for auxiliary diagnosis or screening or auxiliary screening of systemic lupus erythematosus. The invention also provides an application of a substance for detecting the relative expression quantity of the IFIH1 gene and the CFLAR gene and a carrier loaded with the following combined index C value model formula in preparation of a product for auxiliary diagnosis or screening or auxiliary screening of systemic lupus erythematosus. The specific gene expression marker IFIH1 and / or CFLAR of the neutrophile granulocyte is selected by focusing the unique change of the SLE neutrophile granulocyte to assist the clinical early-stage identification and diagnosis of the SLE, and an IFIH1 and CFLAR combined diagnosis model is constructed, so that the diagnosis or screening of the SLE is realized; the kit has high sensitivity and specificity.

The invention discloses a traditional Chinese medicine composition for preventing / treating systemic lupus erythematosus and application thereof.The traditional Chinese medicine composition is reasonably combined according to etiology and pathogenesis of systemic lupus erythematosus, pseudo-ginseng, ginseng, glossy privet fruit and syngnathus serve as monarch drugs, and the traditional Chinese medicine composition has the effects of promoting blood circulation to remove blood stasis, nourishing the liver and tonifying the kidney and directly tonifying yin deficiency of the liver and the kidney; salvia miltiorrhiza, safflower, peach kernel, American ginseng, codonopsis pilosula, prepared rhizome of rehmannia, wolfberry, mulberry and panax japonicus are taken as ministerial drugs and are matched to assist the monarch drugs and clear stasis heat, cornu cervi pantotrichum, herba epimedii, hippocampus, pericarpium citri reticulatae, polygonum multiflorum, angelica sinensis, radix paeoniae alba, rhizoma polygonati and dog kidney are taken as adjuvant and conductant drugs and assist the monarch and ministerial drugs to harmonize yin and yang, all the drugs are matched and have a synergistic effect, and the effects of nourishing kidney and replenishing essence, reinforcing qi and nourishing yin, promoting blood circulation to remove meridian obstruction, warming yang and removing stasis can be achieved. The traditional Chinese medicine can treat both symptoms and root causes, and can effectively treat systemic lupus erythematosus.

The invention discloses a preparation method and application of an astragalus flavonoid extract with an effect of treating systemic lupus erythematosus, and belongs to the technical field of pharmaceutical preparations. The preparation method disclosed by the invention comprises the following steps: screening components for treating systemic lupus erythematosus target protein in astragalus membranaceus by adopting reverse network pharmacology; the preparation method comprises the following steps: preparing an astragalus flavonoid substance by adopting an ultrasonic-assisted deep eutectic solvent method, and extracting the astragalus flavonoid substance by using ethyl acetate to obtain an astragalus flavonoid ethyl acetate extract; preparing magnetic nanoparticles of which the surfaces are adsorbed with the target protein; and carrying out micromolecule fishing on the astragalus flavone ethyl acetate extract by adopting the magnetic nanoparticles, so as to obtain the astragalus flavone extract with the effect of treating systemic lupus erythematosus. The radix astragali flavonoid extract prepared by the invention has a higher curative effect on systemic lupus erythematosus, and has a better effect than the existing medicine under the same dosage.

To provide compounds as new proline derivatives, and to provide a pharmaceutical composition comprising the compounds for the treatment of diseases such as systemic lupus erythematosus, systemic sclerosis, non-alcoholic steatohepatitis, interstitial lung disease and idiopathic pulmonary fibrosis.SOLUTION: There are provided new proline derivatives of formula (I) as cGAS inhibitors, or pharmaceutical compositions comprising a prodrug, a pharmaceutically acceptable salt, or a stereoisomer of the compound.SELECTED DRAWING: None

The invention relates to a cyclopeptide inhibitor aiming at human STING (stimulating interferon gene) and application of the cyclopeptide inhibitor. The cyclic peptide can specifically bind to and inhibit activation of human STING. The invention also provides a nanoparticle delivery system for loading the cyclopeptide on a cationic polymer PBAE and an amphiphilic polymer pDMA-pEPEMA, and a preparation method of the nanoparticle delivery system. The cyclic peptide and the nanoparticles thereof can be used for preparing medicines for treating autoimmune diseases (such as systemic lupus erythematosus and the like) caused by excessive activation of the cGAS-STING signal pathway. Compared with the existing small molecule STING inhibitor, the cyclopeptide inhibitor provided by the invention has higher specificity, stability and inhibition effect.

The invention belongs to the field of new application of medicines, and particularly relates to application of SIRT4-IN-1 in preparation of medicines for treating autoimmune diseases. It is found for the first time that SIRT4-IN-1 reduces the activation degree of immune response induced by HSV-1 virus infection by up-regulating acetylation modification of cGAS, inhibits abnormal activation of immune response in Trex1 deficient mouse cells and peripheral blood mononuclear cells of systemic lupus erythematosus patients, and improves abnormal activation of autoimmune response. The invention provides a new candidate drug for clinical treatment of systemic lupus erythematosus.

The present invention relates methods of producing B cell depletion in autoimmune diseases. More specifically, the invention shows the use of CD-19 bispecific targeting molecules to effectively treat autoimmune disorders such as Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA), and Sjögren's disease (SjD).

The invention belongs to the field of immune cell therapy, and particularly relates to application of a double-target CAR-T cell to treatment of systemic lupus erythematosus and other B-cell autoimmune diseases. A first target point of the chimeric antigen receptor is CD19, a second target point of the chimeric antigen receptor is BCMA, and the chimeric antigen receptor with the Loop structure is specifically the chimeric antigen receptor with the Loop structure, and the structure of the chimeric antigen receptor with the Loop structure is shown as follows: L-VL, CD19-VH, BCMA-VL, BCMA-VH and CD19-H-TM-C-CD3zeta; the BCMA-CD19 CAR-T cell transduced by the chimeric antigen receptor can more comprehensively block the way of generating the autoantibody in the process of targeting CD19 and BCMA, and can more completely cover B cells, plasma mother cells and plasma cells which generate the autoantibody and are in a plurality of differentiation stages; therefore, the double-target CAR-T therapy designed on the basis of the concept can be used for treating refractory SLE, and is expected to obtain quicker relieving and deeper and lasting curative effects.

The present invention provides compounds of formula I for the treatment of diseases such as systemic lupus erythematosus, systemic sclerosis (SSc), interferonosis, nonalcoholic steatohepatitis (NASH), interstitial lung disease (ILD), and idiopathic pulmonary fibrosis (IPF). JPEG2026504613000125.jpg8493 (in the formula, R 1 , R 2 , R 3 , R 4 , A, D, E, G, J, K, and L are as defined in claim 1), and prodrugs, deuterated analogs, and pharmaceutically acceptable salts thereof.

Provided is a circular RNA encoding CARs and the use thereof to create immune cells that target specific diseases, e. g., lymphoma, multiple myeloma and leukemia and auntoimmune diseases, such as systemic lupus erythematousus, lupus nephritis and myasthenia gravis.

The invention relates to a mesenchymal stem cell immunomodulatory function enhancing technology based on gene editing. The invention relates to the field of biomedical engineering and regenerative medicine, and particularly provides a method for enhancing the immune regulation function of mesenchymal stem cells through a CRISPR-Cas9 gene editing technology, and aims at up-regulating IDO1, IL-10 and other key genes in a targeted manner and remarkably improving the excessive immune response inhibition capability of MSCs. The technology can be used for developing high-efficiency and low-toxicity novel cell drugs for treating autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus.

The invention relates to an application of a small molecule medicine STK000311 in a medicine for treating a cGAS-STING pathway abnormal activation disease, and belongs to the technical field of biological medicines. According to the application disclosed by the invention, the small-molecular medicine STK000311 or the pharmaceutically acceptable salt of the small-molecular medicine STK000311 serving as the cGAS-STING signaling pathway inhibitor has an obvious treatment effect on the cGAS-STING pathway abnormal activation diseases for the first time, and verification experiments show that the small-molecular medicine STK000311 can be used for obviously inhibiting the activity of human cGAS protein in a targeted manner and inhibiting cGAS-mediated antiviral immune response; the transcription level of ISGs in PBMCs (peripheral blood mononuclear cells) of an SLE (systemic lupus erythematosus) patient is inhibited, the fact that the small-molecule medicine STK000311 has huge potential of developing cGAS activity related diseases is fully proved, a novel treatment medicine is provided for clinic, and the small-molecule medicine STK000311 has good clinical application value and wide application prospect.

A method for characterizing disease activity in a systemic lupus erythematosus patient (SLE), comprising obtaining a dataset associated with a blood, serum, plasma or urine sample from the patient, assessing the dataset for a presence or an amount of protein expression of at least one innate serum or plasma mediator, assessing the dataset for a presence or an amount of protein expression of at least one adaptive serum or plasma mediator biomarker, assessing the dataset for a presence or an amount of at least one chemokine / adhesion molecule biomarker, assessing the dataset for a presence or an amount of at least one soluble TNF superfamily biomarker, assessing the dataset for a presence or an amount of at least one inflammatory mediator biomarker, assessing the dataset for a presence or an amount at least one SLE-associated autoantibody specificity biomarker and calculating a Lupus Disease Activity Immune Index (LDAII) score.

The application relates to methods for the diagnosis, treatment, and prevention of autoimmune and / or inflammatory disease such as systemic lupus erythematosus (SLE) and lupus nephritis.

The invention discloses a biomarker for diagnosing systemic lupus erythematosus and lupus nephritis and application of the biomarker, and relates to the technical field of biological medicines. The biomarker is an ISG15hiCD16 < + > mononuclear cell. According to the application disclosed by the invention, the ISG15hiCD16 + mononuclear cell subpopulation is found to be obviously increased in an SLE (systemic lupus erythematosus) patient. The invention also finds that the expression level of the ISG15hiCD16 + mononuclear cell subpopulation is positively correlated with the disease activity of the SLE patient, and the expression level of the ISG15hiCD16 + mononuclear cell subpopulation of the SLE patient with the kidney enduring expression is obviously higher than that of the SLE patient without the kidney enduring expression. The working characteristic curve analysis of a subject shows that the ISG15hiCD16 + mononuclear cell subset has better sensitivity and specificity for diagnosing the SLE and the LN, and has important significance for clinical auxiliary diagnosis of the SLE and the LN and illness state evaluation.

The disclosure herein relates to the development and production of novel antibodies and antigen binding fragments thereof that bind TL1 A and that are useful in the treatment, prevention and diagnosis of a disease, disorder or inflammation including, for example, autoimmune diseases including rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, systemic lupus erythematosus, asthma, ulcerative colitis, Crohn's disease, psoriasis, primary biliary cirrhosis, primary biliary cholangitis, ankylosing spondylitis, and fibrosis including intestinal fibrosis, pulmonary fibrosis, and liver fibrosis. Some of the elements of final antibody structure being designed de novo by a computer system and its data training set without reference to a specific reference molecule.

The invention relates to the technical field of biological medicine, and provides application of TRIM69 in preparation of a kit for auxiliary diagnosis of systemic lupus erythematosus. The kit assists in diagnosing systemic lupus erythematosus by detecting the TRIM69 level. Through the mRNA expression quantity of the TRIM69 and the expression quantity and / or concentration of the protein, the auxiliary diagnosis of the systemic lupus erythematosus is realized, and the TRIM69 as a biomarker has important values in the aspects of auxiliary diagnosis, disease activity monitoring, prognosis evaluation, diagnosis efficiency improvement and the like. Not only can a doctor be helped to recognize a high-risk patient earlier, but also a basis can be provided for individualized treatment, so that the long-term prognosis of the systemic lupus erythematosus patient is improved.

Fusion polypeptides are provided and comprise at least two ligand binding domains and a fragment crystallizable (Fc) region of immunoglobulin G (IgG). The ligand binding domains include an amino acid sequence selected from the group consisting of SEQ ID NOS: 1-25 and / or one of the at least two ligand binding domains binds modulates B cell activity while the other modulates T cell activity. Isolated nucleic acids, vectors, and isolated cells encoding or including the fusion peptides are further provided. Pharmaceutical compositions include the fusion peptides and a pharmaceutically-acceptable vehicle, carrier, or excipient. Methods of treating Sjögren's Syndrome and / or Systemic Lupus Erythematosus are also provided and comprise administering to a subject in need thereof the fusion polypeptide including the two ligand binding domains and the Fc region of IgG.